CN111000218A - Formula product capable of adjusting intestines and stomach and preventing cerebral thrombosis - Google Patents
Formula product capable of adjusting intestines and stomach and preventing cerebral thrombosis Download PDFInfo
- Publication number
- CN111000218A CN111000218A CN201911112893.8A CN201911112893A CN111000218A CN 111000218 A CN111000218 A CN 111000218A CN 201911112893 A CN201911112893 A CN 201911112893A CN 111000218 A CN111000218 A CN 111000218A
- Authority
- CN
- China
- Prior art keywords
- parts
- oligosaccharide
- mass
- stomach
- cerebral thrombosis
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 210000000936 intestine Anatomy 0.000 title claims abstract description 31
- 206010008132 Cerebral thrombosis Diseases 0.000 title claims abstract description 24
- 201000001429 Intracranial Thrombosis Diseases 0.000 title claims abstract description 24
- 210000002784 stomach Anatomy 0.000 title claims abstract description 22
- 235000013406 prebiotics Nutrition 0.000 claims abstract description 24
- 239000002994 raw material Substances 0.000 claims abstract description 20
- 230000001105 regulatory effect Effects 0.000 claims abstract description 19
- 235000013557 nattō Nutrition 0.000 claims abstract description 14
- 108010073771 Soybean Proteins Proteins 0.000 claims abstract description 13
- 235000010449 maltitol Nutrition 0.000 claims abstract description 13
- VQHSOMBJVWLPSR-WUJBLJFYSA-N maltitol Chemical compound OC[C@H](O)[C@@H](O)[C@@H]([C@H](O)CO)O[C@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O VQHSOMBJVWLPSR-WUJBLJFYSA-N 0.000 claims abstract description 13
- 229940035436 maltitol Drugs 0.000 claims abstract description 13
- 239000000845 maltitol Substances 0.000 claims abstract description 13
- 235000019710 soybean protein Nutrition 0.000 claims abstract description 13
- 229920001542 oligosaccharide Polymers 0.000 claims abstract description 12
- 150000002482 oligosaccharides Chemical class 0.000 claims abstract description 12
- 229920001202 Inulin Polymers 0.000 claims abstract description 11
- JYJIGFIDKWBXDU-MNNPPOADSA-N inulin Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)OC[C@]1(OC[C@]2(OC[C@]3(OC[C@]4(OC[C@]5(OC[C@]6(OC[C@]7(OC[C@]8(OC[C@]9(OC[C@]%10(OC[C@]%11(OC[C@]%12(OC[C@]%13(OC[C@]%14(OC[C@]%15(OC[C@]%16(OC[C@]%17(OC[C@]%18(OC[C@]%19(OC[C@]%20(OC[C@]%21(OC[C@]%22(OC[C@]%23(OC[C@]%24(OC[C@]%25(OC[C@]%26(OC[C@]%27(OC[C@]%28(OC[C@]%29(OC[C@]%30(OC[C@]%31(OC[C@]%32(OC[C@]%33(OC[C@]%34(OC[C@]%35(OC[C@]%36(O[C@@H]%37[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O%37)O)[C@H]([C@H](O)[C@@H](CO)O%36)O)[C@H]([C@H](O)[C@@H](CO)O%35)O)[C@H]([C@H](O)[C@@H](CO)O%34)O)[C@H]([C@H](O)[C@@H](CO)O%33)O)[C@H]([C@H](O)[C@@H](CO)O%32)O)[C@H]([C@H](O)[C@@H](CO)O%31)O)[C@H]([C@H](O)[C@@H](CO)O%30)O)[C@H]([C@H](O)[C@@H](CO)O%29)O)[C@H]([C@H](O)[C@@H](CO)O%28)O)[C@H]([C@H](O)[C@@H](CO)O%27)O)[C@H]([C@H](O)[C@@H](CO)O%26)O)[C@H]([C@H](O)[C@@H](CO)O%25)O)[C@H]([C@H](O)[C@@H](CO)O%24)O)[C@H]([C@H](O)[C@@H](CO)O%23)O)[C@H]([C@H](O)[C@@H](CO)O%22)O)[C@H]([C@H](O)[C@@H](CO)O%21)O)[C@H]([C@H](O)[C@@H](CO)O%20)O)[C@H]([C@H](O)[C@@H](CO)O%19)O)[C@H]([C@H](O)[C@@H](CO)O%18)O)[C@H]([C@H](O)[C@@H](CO)O%17)O)[C@H]([C@H](O)[C@@H](CO)O%16)O)[C@H]([C@H](O)[C@@H](CO)O%15)O)[C@H]([C@H](O)[C@@H](CO)O%14)O)[C@H]([C@H](O)[C@@H](CO)O%13)O)[C@H]([C@H](O)[C@@H](CO)O%12)O)[C@H]([C@H](O)[C@@H](CO)O%11)O)[C@H]([C@H](O)[C@@H](CO)O%10)O)[C@H]([C@H](O)[C@@H](CO)O9)O)[C@H]([C@H](O)[C@@H](CO)O8)O)[C@H]([C@H](O)[C@@H](CO)O7)O)[C@H]([C@H](O)[C@@H](CO)O6)O)[C@H]([C@H](O)[C@@H](CO)O5)O)[C@H]([C@H](O)[C@@H](CO)O4)O)[C@H]([C@H](O)[C@@H](CO)O3)O)[C@H]([C@H](O)[C@@H](CO)O2)O)[C@@H](O)[C@H](O)[C@@H](CO)O1 JYJIGFIDKWBXDU-MNNPPOADSA-N 0.000 claims abstract description 11
- 229940029339 inulin Drugs 0.000 claims abstract description 11
- 244000068988 Glycine max Species 0.000 claims abstract description 10
- 235000010469 Glycine max Nutrition 0.000 claims abstract description 10
- HEBKCHPVOIAQTA-NGQZWQHPSA-N d-xylitol Chemical compound OC[C@H](O)C(O)[C@H](O)CO HEBKCHPVOIAQTA-NGQZWQHPSA-N 0.000 claims abstract description 10
- 235000021255 galacto-oligosaccharides Nutrition 0.000 claims abstract description 10
- 150000003271 galactooligosaccharides Chemical class 0.000 claims abstract description 10
- DLRVVLDZNNYCBX-RTPHMHGBSA-N isomaltose Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1OC[C@@H]1[C@@H](O)[C@H](O)[C@@H](O)C(O)O1 DLRVVLDZNNYCBX-RTPHMHGBSA-N 0.000 claims abstract description 10
- 239000008187 granular material Substances 0.000 claims description 6
- 239000000843 powder Substances 0.000 claims description 6
- 238000002360 preparation method Methods 0.000 claims description 6
- 239000003826 tablet Substances 0.000 claims description 6
- 241000007126 Codonopsis pilosula Species 0.000 claims description 3
- 235000013361 beverage Nutrition 0.000 claims description 3
- 229940002508 ginger extract Drugs 0.000 claims description 3
- 235000020708 ginger extract Nutrition 0.000 claims description 3
- 235000020717 hawthorn extract Nutrition 0.000 claims description 3
- 235000012907 honey Nutrition 0.000 claims description 3
- 239000000203 mixture Substances 0.000 claims description 3
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 3
- 235000013305 food Nutrition 0.000 abstract description 8
- 206010010774 Constipation Diseases 0.000 abstract description 7
- 208000024891 symptom Diseases 0.000 abstract description 6
- 235000013402 health food Nutrition 0.000 abstract description 5
- 206010000059 abdominal discomfort Diseases 0.000 abstract description 2
- 230000008901 benefit Effects 0.000 abstract description 2
- 230000001684 chronic effect Effects 0.000 abstract description 2
- 208000018522 Gastrointestinal disease Diseases 0.000 description 8
- 230000006872 improvement Effects 0.000 description 6
- 206010008118 cerebral infarction Diseases 0.000 description 5
- 201000001320 Atherosclerosis Diseases 0.000 description 4
- 244000063299 Bacillus subtilis Species 0.000 description 4
- 235000014469 Bacillus subtilis Nutrition 0.000 description 4
- 206010012735 Diarrhoea Diseases 0.000 description 4
- 208000026106 cerebrovascular disease Diseases 0.000 description 4
- 201000010099 disease Diseases 0.000 description 4
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 4
- 239000006047 digesta Substances 0.000 description 3
- 239000003814 drug Substances 0.000 description 3
- 230000000694 effects Effects 0.000 description 3
- 239000000463 material Substances 0.000 description 3
- 239000008280 blood Substances 0.000 description 2
- 210000004369 blood Anatomy 0.000 description 2
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 2
- 230000015271 coagulation Effects 0.000 description 2
- 238000005345 coagulation Methods 0.000 description 2
- 230000037213 diet Effects 0.000 description 2
- 235000005911 diet Nutrition 0.000 description 2
- 230000000968 intestinal effect Effects 0.000 description 2
- 210000004185 liver Anatomy 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 208000003343 Antiphospholipid Syndrome Diseases 0.000 description 1
- 201000005657 Antithrombin III deficiency Diseases 0.000 description 1
- 208000002381 Brain Hypoxia Diseases 0.000 description 1
- 201000006474 Brain Ischemia Diseases 0.000 description 1
- 206010008120 Cerebral ischaemia Diseases 0.000 description 1
- 208000031226 Hyperlipidaemia Diseases 0.000 description 1
- 206010020772 Hypertension Diseases 0.000 description 1
- 206010028851 Necrosis Diseases 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- 208000031481 Pathologic Constriction Diseases 0.000 description 1
- 102000001938 Plasminogen Activators Human genes 0.000 description 1
- 108010001014 Plasminogen Activators Proteins 0.000 description 1
- 208000008601 Polycythemia Diseases 0.000 description 1
- 101800004937 Protein C Proteins 0.000 description 1
- 102000017975 Protein C Human genes 0.000 description 1
- 229940096437 Protein S Drugs 0.000 description 1
- 102000029301 Protein S Human genes 0.000 description 1
- 108010066124 Protein S Proteins 0.000 description 1
- 101800001700 Saposin-D Proteins 0.000 description 1
- 206010043561 Thrombocytopenic purpura Diseases 0.000 description 1
- 208000005485 Thrombocytosis Diseases 0.000 description 1
- 208000007536 Thrombosis Diseases 0.000 description 1
- 230000002159 abnormal effect Effects 0.000 description 1
- 230000009858 acid secretion Effects 0.000 description 1
- 230000004075 alteration Effects 0.000 description 1
- 230000003143 atherosclerotic effect Effects 0.000 description 1
- 230000002457 bidirectional effect Effects 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 230000036770 blood supply Effects 0.000 description 1
- 210000004204 blood vessel Anatomy 0.000 description 1
- 210000004556 brain Anatomy 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- 150000001720 carbohydrates Chemical class 0.000 description 1
- 235000014633 carbohydrates Nutrition 0.000 description 1
- 210000001627 cerebral artery Anatomy 0.000 description 1
- 235000012000 cholesterol Nutrition 0.000 description 1
- 208000029078 coronary artery disease Diseases 0.000 description 1
- 230000001054 cortical effect Effects 0.000 description 1
- 230000006866 deterioration Effects 0.000 description 1
- 206010012601 diabetes mellitus Diseases 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 238000000855 fermentation Methods 0.000 description 1
- 230000004151 fermentation Effects 0.000 description 1
- FTSSQIKWUOOEGC-RULYVFMPSA-N fructooligosaccharide Chemical compound OC[C@H]1O[C@@](CO)(OC[C@@]2(OC[C@@]3(OC[C@@]4(OC[C@@]5(OC[C@@]6(OC[C@@]7(OC[C@@]8(OC[C@@]9(OC[C@@]%10(OC[C@@]%11(O[C@H]%12O[C@H](CO)[C@@H](O)[C@H](O)[C@H]%12O)O[C@H](CO)[C@@H](O)[C@@H]%11O)O[C@H](CO)[C@@H](O)[C@@H]%10O)O[C@H](CO)[C@@H](O)[C@@H]9O)O[C@H](CO)[C@@H](O)[C@@H]8O)O[C@H](CO)[C@@H](O)[C@@H]7O)O[C@H](CO)[C@@H](O)[C@@H]6O)O[C@H](CO)[C@@H](O)[C@@H]5O)O[C@H](CO)[C@@H](O)[C@@H]4O)O[C@H](CO)[C@@H](O)[C@@H]3O)O[C@H](CO)[C@@H](O)[C@@H]2O)[C@@H](O)[C@@H]1O FTSSQIKWUOOEGC-RULYVFMPSA-N 0.000 description 1
- 229940107187 fructooligosaccharide Drugs 0.000 description 1
- 230000006870 function Effects 0.000 description 1
- 210000001035 gastrointestinal tract Anatomy 0.000 description 1
- 208000033666 hereditary antithrombin deficiency Diseases 0.000 description 1
- 230000007954 hypoxia Effects 0.000 description 1
- 230000036039 immunity Effects 0.000 description 1
- 230000008991 intestinal motility Effects 0.000 description 1
- 208000001286 intracranial vasospasm Diseases 0.000 description 1
- 150000002632 lipids Chemical class 0.000 description 1
- 210000005229 liver cell Anatomy 0.000 description 1
- 230000008338 local blood flow Effects 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 235000012054 meals Nutrition 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 238000000034 method Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000017074 necrotic cell death Effects 0.000 description 1
- 208000020470 nervous system symptom Diseases 0.000 description 1
- 235000003715 nutritional status Nutrition 0.000 description 1
- 239000000575 pesticide Substances 0.000 description 1
- 229940127126 plasminogen activator Drugs 0.000 description 1
- 231100000614 poison Toxicity 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 230000003449 preventive effect Effects 0.000 description 1
- 239000006041 probiotic Substances 0.000 description 1
- 230000000529 probiotic effect Effects 0.000 description 1
- 235000018291 probiotics Nutrition 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 229960000856 protein c Drugs 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- 208000007056 sickle cell anemia Diseases 0.000 description 1
- 230000036262 stenosis Effects 0.000 description 1
- 208000037804 stenosis Diseases 0.000 description 1
- 238000006467 substitution reaction Methods 0.000 description 1
- 230000008961 swelling Effects 0.000 description 1
- CEIZFXOZIQNICU-UHFFFAOYSA-N tenuazonic acid Chemical compound CCC(C)C1NC(=O)C(C(C)=O)=C1O CEIZFXOZIQNICU-UHFFFAOYSA-N 0.000 description 1
- 230000008719 thickening Effects 0.000 description 1
- 230000002446 thrombocytic effect Effects 0.000 description 1
- 239000003440 toxic substance Substances 0.000 description 1
- UFTFJSFQGQCHQW-UHFFFAOYSA-N triformin Chemical compound O=COCC(OC=O)COC=O UFTFJSFQGQCHQW-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L11/00—Pulses, i.e. fruits of leguminous plants, for production of food; Products from legumes; Preparation or treatment thereof
- A23L11/50—Fermented pulses or legumes; Fermentation of pulses or legumes based on the addition of microorganisms
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L2/00—Non-alcoholic beverages; Dry compositions or concentrates therefor; Their preparation
- A23L2/38—Other non-alcoholic beverages
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
Landscapes
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Food Science & Technology (AREA)
- Health & Medical Sciences (AREA)
- Nutrition Science (AREA)
- Chemical & Material Sciences (AREA)
- Polymers & Plastics (AREA)
- Microbiology (AREA)
- Agronomy & Crop Science (AREA)
- Botany (AREA)
- Biotechnology (AREA)
- Mycology (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Coloring Foods And Improving Nutritive Qualities (AREA)
Abstract
The invention discloses a formula product capable of adjusting intestines and stomach and preventing cerebral thrombosis, which comprises the following raw materials in parts by mass: 20-150 parts of freeze-dried natto, 90-180 parts of soybean protein, 50-130 parts of maltitol and 50-120 parts of prebiotics, wherein each prebiotic comprises the following raw materials in percentage by mass: 0.15-0.8 part of galacto-oligosaccharide, 0.15-0.8 part of xylo-oligosaccharide, 0.1-0.3 part of isomalto-oligosaccharide, 0.1-0.3 part of soybean oligosaccharide and 0.3-0.5 part of inulin. Compared with the prior art, the invention has the advantages that: the health food or the common food can be widely applied to the clinical treatment of chronic gastrointestinal discomfort and cerebral thrombosis, can also be used for preventing cerebral thrombosis in daily life, and can be used as the health food or the common food for regulating the intestines and the stomach to effectively relieve constipation symptoms.
Description
Technical Field
The invention relates to the fields of health-care food, common food, biological products and the like, in particular to a formula product for regulating intestines and stomach and preventing cerebral thrombosis.
Background
Gastrointestinal diseases are common frequently-occurring diseases, the total incidence rate accounts for about 20% of the population, the incidence rate is higher when the people are older, particularly the middle-aged and the elderly with the age of more than 50 years are more common, men are higher than women, if the middle-aged and the elderly are not treated timely, the gastrointestinal diseases have long-term repeated attacks and are easily converted into cancer and swelling, the gastrointestinal diseases are regarded as difficult symptoms by doctors all the time, once the gastrointestinal diseases are treated timely and are taken for a long time, the gastrointestinal diseases can be controlled or cured, the gastrointestinal diseases are of various types, and the gastrointestinal diseases are often ignored by people due to atypical symptoms, particularly some symptoms which are not obvious after meals.
Cerebral thrombosis is the most common type of cerebral infarction, and is caused by atherosclerosis of main cerebral arteries or cortical branches, such as blood vessel thickening, lumen stenosis occlusion and thrombosis, which cause reduction of local blood flow or blood supply interruption of brain, and softening and necrosis caused by cerebral ischemia and hypoxia to generate focal nervous system symptoms, wherein atherosclerosis is the basic cause of the disease, which causes atherosclerotic cerebral infarction, often accompanied by hypertension, which is caused by atherosclerosis, diabetes and hyperlipidemia can also accelerate the process of atherosclerosis, and the patients with blood system diseases such as polycythemia, thrombocythemia, thrombocytic thrombocytopenia purpura, diffuse intravascular coagulation, sickle cell anemia and the like are rare; some cerebral infarction cases, although image examination confirmed, but difficult to find the exact cause, possible causes include cerebral vasospasm, unknown sources of microemboli, antiphospholipid antibody syndrome protein C and protein S abnormal, antithrombin III deficiency, plasminogen activator incomplete release with high coagulation state.
In medicine, the prevention and treatment effects on the two diseases are poor, so that the design of a formula product for regulating intestines and stomach and preventing cerebral thrombosis is imperative.
Disclosure of Invention
The invention aims to solve the technical problems that medical treatment means for gastrointestinal diseases and cerebral thrombosis are not many in types, actual treatment effect is poor, time consumption is too long, physical burden of patients is increased, economic burden of the patients is increased, time consumption and material consumption are increased in the past, the product is matched with medicine for treatment, discomfort of intestines and stomach is effectively relieved, the effect of bidirectional regulation is achieved for constipation and stool unshaped, and further deterioration is prevented in a preventive manner before cerebral thrombosis and cerebral infarction are formed.
In order to solve the technical problems, the technical scheme provided by the invention is as follows: a formula product for regulating intestines and stomach and preventing cerebral thrombosis comprises the following raw materials in parts by mass: 20-150 parts of freeze-dried natto, 90-180 parts of soybean protein, 50-130 parts of maltitol and 50-120 parts of prebiotics.
Compared with the prior art, the invention has the advantages that: the health food or the common food for regulating the intestines and the stomach can effectively regulate the functions of the intestines and the stomach and prevent the formation of cerebral thrombosis, is used in a health food or a common food mode, is widely applied to relieving and preventing chronic intestine and stomach discomfort, constipation, diarrhea, unformed stool and cerebral thrombosis, and can also effectively relieve constipation symptoms as the health food or the common food for regulating the intestines and the stomach.
As an improvement, the feed comprises the following raw materials in parts by mass: 25-65 parts of freeze-dried natto, 120-170 parts of soybean protein, 60-125 parts of maltitol and 55-110 parts of prebiotics.
As an improvement, the feed comprises the following raw materials in parts by mass: 30-60 parts of freeze-dried natto, 130-160 parts of soybean protein, 80-100 parts of maltitol and 70-90 parts of prebiotics.
As an improvement, each part of prebiotics comprises the following raw materials by mass ratio: 0.05-1.0 part of galacto-oligosaccharide, 0.07-1.2 parts of xylo-oligosaccharide, 0.02-0.5 part of isomalto-oligosaccharide, 0.03-0.5 part of soybean oligosaccharide and 0.2-0.8 part of inulin.
As an improvement, each part of prebiotics comprises the following raw materials by mass ratio: 0.1-0.9 part of galacto-oligosaccharide, 0.12-1.0 part of xylo-oligosaccharide, 0.08-0.4 part of isomalto-oligosaccharide, 0.07-0.35 part of soybean oligosaccharide and 0.26-0.6 part of inulin.
As an improvement, each part of prebiotics comprises the following raw materials by mass ratio: 0.15-0.8 part of galacto-oligosaccharide, 0.15-0.8 part of xylo-oligosaccharide, 0.1-0.3 part of isomalto-oligosaccharide, 0.1-0.3 part of soybean oligosaccharide and 0.3-0.5 part of inulin.
As an improvement, the preparation method of a formula product for regulating intestines and stomach and preventing cerebral thrombosis comprises the following steps:
s1, mixing 30-60 parts by mass of freeze-dried natto, 130-160 parts by mass of soybean protein, 80-100 parts by mass of maltitol and 70-90 parts by mass of prebiotics with 0-15 parts by mass of hawthorn extract, 0-15 parts by mass of dried ginger extract and 0-20 parts by mass of codonopsis pilosula extract according to a proportion, and preparing the mixture into one of powder, granules or tablets;
s2, adding honey into one of the powder, the granules or the tablets obtained in the step S1, and preparing the beverage by using the rest of water to finish the preparation.
Detailed Description
When the invention is specifically implemented, the formula product for regulating intestines and stomach and preventing cerebral thrombosis comprises the following raw materials in parts by mass: 20-150 parts of freeze-dried natto, 90-180 parts of soybean protein, 50-130 parts of maltitol and 50-120 parts of prebiotics.
Comprises the following raw materials in parts by mass: 25-65 parts of freeze-dried natto, 120-170 parts of soybean protein, 60-125 parts of maltitol and 55-110 parts of prebiotics.
Comprises the following raw materials in parts by mass: 30-60 parts of freeze-dried natto, 130-160 parts of soybean protein, 80-100 parts of maltitol and 70-90 parts of prebiotics.
Each part of prebiotics comprises the following raw materials in percentage by mass: 0.05-1.0 part of galacto-oligosaccharide, 0.07-1.2 parts of xylo-oligosaccharide, 0.02-0.5 part of isomalto-oligosaccharide, 0.03-0.5 part of soybean oligosaccharide and 0.2-0.8 part of inulin.
Each part of prebiotics comprises the following raw materials in percentage by mass: 0.1-0.9 part of galacto-oligosaccharide, 0.12-1.0 part of xylo-oligosaccharide, 0.08-0.4 part of isomalto-oligosaccharide, 0.07-0.35 part of soybean oligosaccharide and 0.26-0.6 part of inulin.
Each part of prebiotics comprises the following raw materials in percentage by mass: 0.15-0.8 part of galacto-oligosaccharide, 0.15-0.8 part of xylo-oligosaccharide, 0.1-0.3 part of isomalto-oligosaccharide, 0.1-0.3 part of soybean oligosaccharide and 0.3-0.5 part of inulin.
The preparation method of the formula product for regulating intestines and stomach and preventing cerebral thrombosis comprises the following steps: s1, mixing 30-60 parts by mass of freeze-dried natto, 130-160 parts by mass of soybean protein, 80-100 parts by mass of maltitol and 70-90 parts by mass of prebiotics with 0-15 parts by mass of hawthorn extract, 0-15 parts by mass of dried ginger extract and 0-20 parts by mass of codonopsis pilosula extract according to a proportion, and preparing the mixture into one of powder, granules or tablets; s2, adding honey into one of the powder, the granules or the tablets obtained in the step S1, and preparing the beverage by using the rest of water to finish the preparation.
The working principle of the invention is as follows: the bacillus natto (bacillus subtilis) and the prebiotics in the natto can help to regulate intestinal flora and improve microecology and environment, intestinal gas is generated through fermentation to increase the volume of the intestines so as to shorten the stay time of digesta in the intestines, constipation is caused by long stay time of the digesta in the intestines, the constipation is naturally helped to resist the constipation after short time, when the balance of the probiotic flora in the intestines is broken, the pH value in the intestines is unbalanced, diarrhea can be caused, the bacillus natto (bacillus subtilis) is supplemented, the pH value of the intestines can be helped to recover the normal intestinal tract pH value, and diarrhea and stool shapeless symptoms can be relieved. In addition, many carbohydrates increase the moisture content of the intestine and acid secretion stimulates intestinal motility, which also reduces the transit time of digesta through the intestine and has a bi-directional regulatory effect on diarrhea.
In the aspect of regulating blood fat, the functional oligosaccharide can regulate the fat metabolism mechanism in the liver, the food of a rat contains 10 percent of inulin and fructo-oligosaccharide, the serum lipid can be obviously reduced, the contents of cholesterol and triglyceride are reduced, and the coronary heart disease can be prevented and treated to a certain extent.
In the aspect of resisting harmful substances in the diet, the functional oligosaccharide can resist the harmful substances in the diet, such as medicines, pesticides, toxic substances and the like, so that the level of vivotoxin is reduced, the nutritional status is improved, the growth of liver cells is assisted, and the immunity of a human body is improved, thereby playing a role in protecting the liver.
Furthermore, the terms "first", "second" and "first" are used for descriptive purposes only and are not to be construed as indicating or implying relative importance or implicitly indicating the number of technical features indicated. Thus, a feature defined as "first" or "second" may explicitly or implicitly include one or more of that feature, and in the description of the invention, "plurality" means two or more unless explicitly defined otherwise.
In the description herein, reference to the terms "one embodiment," "some embodiments," "an example," "a specific example," or "some examples" or the like means that a particular feature, structure, material, or characteristic described in connection with the embodiment or example is included in at least one embodiment or example of the invention. In this specification, the schematic representations of the terms used above do not necessarily refer to the same embodiment or example. Furthermore, the particular features, structures, materials, or characteristics described may be combined in any suitable manner in any one or more embodiments or examples.
Although embodiments of the present invention have been shown and described above, it is understood that the above embodiments are exemplary and should not be construed as limiting the present invention, and that variations, modifications, substitutions and alterations can be made in the above embodiments by those of ordinary skill in the art without departing from the principle and spirit of the present invention.
Claims (7)
1. A formula product for regulating intestines and stomach and preventing cerebral thrombosis is characterized in that: comprises the following raw materials in parts by mass: 20-150 parts of freeze-dried natto, 90-180 parts of soybean protein, 50-130 parts of maltitol and 50-120 parts of prebiotics.
2. The formula product for regulating intestines and stomach and preventing cerebral thrombosis according to claim 1 is characterized in that: comprises the following raw materials in parts by mass: 25-65 parts of freeze-dried natto, 120-170 parts of soybean protein, 60-125 parts of maltitol and 55-110 parts of prebiotics.
3. The formula product for regulating intestines and stomach and preventing cerebral thrombosis according to claim 1 is characterized in that: comprises the following raw materials in parts by mass: 30-60 parts of freeze-dried natto, 130-160 parts of soybean protein, 80-100 parts of maltitol and 70-90 parts of prebiotics.
4. The formula product for regulating intestines and stomach and preventing cerebral thrombosis according to claim 1 is characterized in that: each part of prebiotics comprises the following raw materials in percentage by mass: 0.05-1.0 part of galacto-oligosaccharide, 0.07-1.2 parts of xylo-oligosaccharide, 0.02-0.5 part of isomalto-oligosaccharide, 0.03-0.5 part of soybean oligosaccharide and 0.2-0.8 part of inulin.
5. The formula product for regulating intestines and stomach and preventing cerebral thrombosis according to claim 4, is characterized in that: each part of prebiotics comprises the following raw materials in percentage by mass: 0.1-0.9 part of galacto-oligosaccharide, 0.12-1.0 part of xylo-oligosaccharide, 0.08-0.4 part of isomalto-oligosaccharide, 0.07-0.35 part of soybean oligosaccharide and 0.26-0.6 part of inulin.
6. The formula product for regulating intestines and stomach and preventing cerebral thrombosis according to claim 4, is characterized in that: each part of prebiotics comprises the following raw materials in percentage by mass: 0.15-0.8 part of galacto-oligosaccharide, 0.15-0.8 part of xylo-oligosaccharide, 0.1-0.3 part of isomalto-oligosaccharide, 0.1-0.3 part of soybean oligosaccharide and 0.3-0.5 part of inulin.
7. The formula product for regulating intestines and stomach and preventing cerebral thrombosis according to claim 4, is characterized in that: the preparation method of the formula product for regulating intestines and stomach and preventing cerebral thrombosis comprises the following steps:
s1, mixing 30-60 parts by mass of freeze-dried natto, 130-160 parts by mass of soybean protein, 80-100 parts by mass of maltitol and 70-90 parts by mass of prebiotics with 0-15 parts by mass of hawthorn extract, 0-15 parts by mass of dried ginger extract and 0-20 parts by mass of codonopsis pilosula extract according to a proportion, and preparing the mixture into one of powder, granules or tablets;
s2, adding honey into one of the powder, the granules or the tablets obtained in the step S1, and preparing the beverage by using the rest of water to finish the preparation.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201911112893.8A CN111000218A (en) | 2019-11-14 | 2019-11-14 | Formula product capable of adjusting intestines and stomach and preventing cerebral thrombosis |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201911112893.8A CN111000218A (en) | 2019-11-14 | 2019-11-14 | Formula product capable of adjusting intestines and stomach and preventing cerebral thrombosis |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN111000218A true CN111000218A (en) | 2020-04-14 |
Family
ID=70112079
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201911112893.8A Pending CN111000218A (en) | 2019-11-14 | 2019-11-14 | Formula product capable of adjusting intestines and stomach and preventing cerebral thrombosis |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN111000218A (en) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN111658658A (en) * | 2020-06-17 | 2020-09-15 | 上海大学 | Application of xylo-oligosaccharide in preparation of medicine for resisting deep venous thrombosis |
Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20160324904A1 (en) * | 2015-05-05 | 2016-11-10 | Ryozo Saito | Supplement for improving immunotolerance, intestinal environment and intestinal tract barrier |
| CN106798252A (en) * | 2017-01-20 | 2017-06-06 | 武汉虹辰远荣生物制品有限公司 | A kind of natto prescription with coordinating intestines and stomach reducing blood lipid thrombus dissolving effect |
| CN109170906A (en) * | 2018-10-15 | 2019-01-11 | 上海拜伦斯维生物科技中心 | The formula of prebiotics generation meal milk shake (prebiotic meal) |
-
2019
- 2019-11-14 CN CN201911112893.8A patent/CN111000218A/en active Pending
Patent Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20160324904A1 (en) * | 2015-05-05 | 2016-11-10 | Ryozo Saito | Supplement for improving immunotolerance, intestinal environment and intestinal tract barrier |
| CN106798252A (en) * | 2017-01-20 | 2017-06-06 | 武汉虹辰远荣生物制品有限公司 | A kind of natto prescription with coordinating intestines and stomach reducing blood lipid thrombus dissolving effect |
| CN109170906A (en) * | 2018-10-15 | 2019-01-11 | 上海拜伦斯维生物科技中心 | The formula of prebiotics generation meal milk shake (prebiotic meal) |
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN111658658A (en) * | 2020-06-17 | 2020-09-15 | 上海大学 | Application of xylo-oligosaccharide in preparation of medicine for resisting deep venous thrombosis |
| CN111658658B (en) * | 2020-06-17 | 2023-08-11 | 上海大学 | Application of xylooligosaccharide in preparation of medicine for resisting deep vein thrombosis |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN101212911B (en) | Infant nutrition with hydrolised proteins | |
| US6929793B2 (en) | Nutritional composition for treating an immune condition | |
| US9783619B2 (en) | Hypoglycemic hyper-branched maltodextrins | |
| US20090143301A1 (en) | High calorie nutritional supplement | |
| CN103238897A (en) | Composite plant solid drink suitable for diabetic patients | |
| CN102273585A (en) | Health-care porridge with effect of relaxing bowel and preparation method thereof | |
| KR20080049330A (en) | Food composition for increasing the satiety and satiation | |
| CN106135797A (en) | A kind of alimentation composition contributing to regulation blood glucose and preparation method thereof | |
| EP2011500A1 (en) | Fat accumulation inhibitor | |
| CN113274481B (en) | Composition for regulating blood sugar and preparation method and application thereof | |
| CN107712874A (en) | Depth hydrolysis' protein prescription powder and technique manufacturing method | |
| KR100716123B1 (en) | Food composition comprising fermented dioscorea batatas decne. and the rhizoma thereof with lactic acid for preventing and improving constipation and obesity | |
| KR20110034732A (en) | A composition of health food containing probiotics with colon health and improved digestion features | |
| CN111000218A (en) | Formula product capable of adjusting intestines and stomach and preventing cerebral thrombosis | |
| JP2017538693A (en) | Composition containing pentose and polyphenol compound | |
| KR100851586B1 (en) | Composition comprising Lactobacillus for inhibiting obesity | |
| JP2017524665A (en) | Food supplements | |
| CN111050779A (en) | Blood sugar spike inhibitor, food and method for producing blood sugar spike inhibitor | |
| KR20150031373A (en) | Phamaceutical and food composition for preventing or treating obesity comprising extract of leaf from Hoppophea rhamnoids as effective component | |
| CN115702654A (en) | Middle-aged and old-aged modified goat milk powder assisting in reducing blood sugar and preparation method thereof | |
| KR20200130030A (en) | Methods for the manufacture of yogurt products with the effect of blood sugar control on diabetics and potential patients | |
| JP2020132621A (en) | Composition for skin gas emission control | |
| of Chinese et al. | Chinese guidelines for medical nutrition therapy for patients with diabetes (2022 edition) | |
| US20220369677A1 (en) | Cereal Compositions Containing Human Milk Oligosaccharides | |
| KR102691618B1 (en) | Probiotics composition comprising fermented milk and whey protein hydrolysates |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| RJ01 | Rejection of invention patent application after publication |
Application publication date: 20200414 |
|
| RJ01 | Rejection of invention patent application after publication |